{
    "Trade/Device Name(s)": [
        "Lyme B. burgdorferi (IgM) MarStripe Test"
    ],
    "Submitter Information": "Immco Diagnostics, Inc. a Trinity Biotech Company",
    "510(k) Number": "K172254",
    "Predicate Device Reference 510(k) Number(s)": [
        "K951709"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LSR"
    ],
    "Summary Letter Date": "July 11, 2017",
    "Summary Letter Received Date": "July 26, 2017",
    "Submission Date": "July 24, 2017",
    "Regulation Number(s)": [
        "21 CFR 866.3830"
    ],
    "Regulation Name(s)": [
        "Treponema pallidum treponemal test reagents"
    ],
    "Analyte Class(es)": [
        "microbiology",
        "immunology"
    ],
    "Analyte(s)": [
        "IgM antibody to Borrelia burgdorferi"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "K2-EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Immunoblot"
    ],
    "Methodologies": [
        "Immunoblot"
    ],
    "Submission Type(s)": [
        "Assay",
        "Kit",
        "Reagent",
        "Control",
        "Conjugate",
        "Substrate",
        "Diluent"
    ],
    "Document Summary": "FDA 510(k) summary for Lyme B. burgdorferi (IgM) MarStripe Test, an immunoblot assay for IgM antibodies to Borrelia burgdorferi in serum or plasma.",
    "Indications for Use Summary": "Qualitative detection of IgM antibody to individual proteins of Borrelia burgdorferi in human serum or plasma as an aid in the diagnosis of Lyme disease.",
    "fda_folder": "Microbiology"
}